基因组拷贝数负荷可区分原发性真皮黑色素瘤的诊断与预后
本研究对20例原发性真皮黑色素瘤(PDM)和23例非表皮皮肤转移性黑色素瘤进行TSO500 panel测序,发现拷贝数变异(CNV)是区分两者的最强特征,转移灶中大规模和局灶性CNV更丰富。结合BRAF拷贝数分析可改善术后风险分层。
要点
- CNV是区分PDM与非表皮皮肤转移灶的最强基因组特征。
- 大规模和局灶性CNV在转移灶中丰富,PDM中缺失。
- PDM无BRAF CNV者术后复发风险较低。
核心结论
- CNV是区分PDM与非表皮皮肤转移灶的最强特征,大规模和局灶性CNV在转移灶中丰富而在PDM中缺失。
- 整合BRAF拷贝数分析与标准临床诊断可改善PDM术后风险分层。
研究设计与样本
- 对20例PDM和23例非表皮皮肤转移性黑色素瘤进行TSO500 panel测序。
- 使用正则化随机森林模型和特征工程识别区分PDM与转移灶的基因组特征。
- 使用Lasso-Cox回归识别无事件生存的预测生物标志物。
主要发现
- PDM和非表皮皮肤转移灶均携带表皮来源黑色素瘤特征性点突变。
- 与非表皮皮肤转移灶相比,PDM具有不同的CNV模式,转移灶显示癌基因获得和抑癌基因丢失。
- 极端局灶性扩增仅见于非表皮皮肤转移灶,PDM中缺失。
- 大规模CNV和局灶性扩增被确定为区分PDM与转移灶的生物标志物。
- 临床诊断为PDM且无BRAF CNV者,术后死亡或疾病进展风险低于临床诊断为转移灶或PDM伴BRAF CNV者。
关键数值与推荐
- 大规模CNV和局灶性扩增是区分PDM与非表皮皮肤转移灶的判别性生物标志物。
- 临床诊断为PDM且无BRAF CNV与术后死亡或疾病进展风险降低相关。
临床怎么用
- 基于panel的基因组测序检测CNV可辅助区分PDM与转移灶,并指导术后风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary dermal melanoma (PDM) is a subtype of melanoma with histological features indiscernible from nonepidermal metastatic cutaneous melanoma deposits, although patients with PDMs have more favourable outcomes than patients with dermal metastases. Despite the histological similarity, it is not known whether the mutational landscapes of PDMs and dermal metastases are also similar, or whether distinct mutational patterns might exist in PDMs. OBJECTIVES: To identify genomic features that distinguish PDMs from nonepidermal cutaneous melanoma metastases, thereby enhancing the accuracy of clinical diagnosis and prognostication. METHODS: Twenty PDMs and 23 nonepidermal cutaneous metastases were sequenced using the TSO500 panel. Genomic features distinguishing PDMs and metastases were identified using the regularized random forest model and feature engineering. Predictive biomarkers of patient event-free survival were identified using Lasso-Cox regression. RESULTS: PDMs and nonepidermal cutaneous metastases harboured point mutations characteristic of melanomas of epidermal origin. Compared with PDMs, metastases exhibited distinct copy number variations (CNVs) that led to gains of oncogenes and losses of tumour suppressor genes. Extreme focal amplifications were uniquely identified in cases of nonepidermal cutaneous metastases but were absent in PDMs. Large-scale CNVs and focal amplifications were identified as discriminative biomarkers between PDMs and metastases. A clinical diagnosis of PDM and an absence of BRAF CNVs collectively were associated with a reduced risk of death or disease progression after surgery vs. a clinical diagnosis of metastasis or of PDM with BRAF CNVs. CONCLUSION: We found that CNVs were the strongest discriminative features between PDMs and nonepidermal cutaneous metastases, with large-scale and focal CNVs abundant in metastases but not in PDMs. Notably, integrating BRAF copy number analysis with standard clinical criteria for diagnosing PDMs improved risk stratification after surgery. These data highlight the ability of panel-based genomic sequencing that enables the detection of CNVs to inform the clinical management of melanoma. Melanoma is the deadliest type of skin cancer. Most often, melanoma starts in the top layer of skin, called the ‘epidermis’. These melanomas can ‘metastasize’. This means they can spread to deeper skin layers and other places in the body. When melanoma metastasizes, people have poorer outcomes. There is a less common subtype of melanoma, known as ‘primary dermal melanoma’ (or ‘PDM’ for short). This begins in the dermis, which is the layer of skin below the epidermis. This type of melanoma looks very similar to metastasized melanoma but is less dangerous. This makes it difficult for doctors to make a correct diagnosis and decide how likely people are to have a relapse in their cancer. So, we need to be able to distinguish PDM from metastasized melanoma. To address this, we analysed DNA from 20 PDMs and 23 metastases from a group of Australian people. We found that changes in DNA called ‘copy number variations’ can tell PDMs and metastases apart. Copy number variation is a type of genetic difference where people have different numbers of copies of a gene. Copy number variations were far more common in dermal metastases than in PDMs. We also found that copy number variations affecting a gene called ‘BRAF’ were linked to patient outcomes. People who had PDMs without copy number variations in BRAF surgically removed were unlikely to have a relapse in their cancer. But, relapses were more common in people who had metastases removed or who had PDMs affected by copy number variations in the BRAF gene removed. Our findings suggest that analysing copy number variation improves the ability of doctors to diagnose and predict relapse in people with dermal melanomas. This could change the way that patients are cared for after surgical removal of these melanomas.
引用
- Zhao P, Chew C, Szeto P, et al. Genomic copy number burden distinguishes the diagnosis and prognosis of primary dermal melanoma. Br J Dermatol. 2026. PMID: 41364704. doi:10.1093/bjd/ljaf507
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。